Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival

Detalhes bibliográficos
Autor(a) principal: Cabral, Sara Carla Moura
Data de Publicação: 2015
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/30456
Resumo: Trabalho final de mestrado integrado em Medicina, apresentado à Faculdade de Medicina da Universidade de Coimbra.
id RCAP_2ce35265847b0d0a9177fc3872f35247
oai_identifier_str oai:estudogeral.uc.pt:10316/30456
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survivalEGFRALKKRASTKI treatmentAdenocarcinomaSurvivalTrabalho final de mestrado integrado em Medicina, apresentado à Faculdade de Medicina da Universidade de Coimbra.OBJECTIVE: Clinical characterization and therapeutic follow-up after histological typing and molecular pathology of Bronchial-Pulmonary Carcinoma MATERIAL AND METHODS: This retrospective study is supported by information collected from a 2011-2013 data basis provided by Instituto de Anatomia Patológica e Patologia Molecular of Faculty of Medicine of Coimbra, concerning histological typing and EGFR, KRAS and ALK mutation status in biopsies, and subsequent follow up of patients, treated at University Hospital of Coimbra, Instituto Português de Oncologia of Coimbra and Hospital of Guarda. RESULTS: Data corresponds to 56 patients with bronchial-pulmonary carcinoma, most (64.3%) of whom were male. Adenocarcinoma was the most common histological type (66.1%), followed by pleomorphic (8.9%), epidermoid (7.1%), adenosquamous (7.1%), large cell (5.4%), sarcomatoid (3.6%) and mucoepidermoid (1.8%) carcinomas. In men, the most common histological type was adenocarcinoma (66.7%), as well as in women (65%). The mean age at diagnosis was 66 years old. About 62.5% had prior history of smoking. 64.3% presented stage IV at diagnosis, 14.3 % IIIB, 7.1 % IIIA and the remaining 14.3% was classified as stage I or II. In 29 cases patients showed mutated epidermal growth factor receptor, comparing with 27 biopsies wild type. About 39.3% received tyrosine kinase inhibitors and 32.1% were treated with chemotherapy combined with radiotherapy. CONCLUSIONS: The study showed higher incidence of bronchial pulmonary carcinoma in men. Adenocarcinoma was the most frequent histological type either in men and women. Smoking habit was prevalent. The majority of patients with mutated status for epidermal growth factor receptor received tyrosine kinase inhibitors (19). For patients wild type, conventional chemotherapy was applied in most cases (19) .The overall survival for patients carrying mutated epidermal growth factor receptor is higher, comparing with the ones wild type, and this result has statistical significance. Radiotherapy was used in association with chemotherapy or alone in palliative therapeutic measures. Most patients presented advanced stages at diagnosis and so curative options were applied only in few cases (11).2015info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://hdl.handle.net/10316/30456http://hdl.handle.net/10316/30456TID:201626268engCabral, Sara Carla Mourainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-01-20T17:48:43Zoai:estudogeral.uc.pt:10316/30456Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:44:20.793794Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
title Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
spellingShingle Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
Cabral, Sara Carla Moura
EGFR
ALK
KRAS
TKI treatment
Adenocarcinoma
Survival
title_short Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
title_full Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
title_fullStr Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
title_full_unstemmed Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
title_sort Bronchial pulmonary carcinoma: molecular and clinical characterization: histology, mutations, staging, therapeutics and survival
author Cabral, Sara Carla Moura
author_facet Cabral, Sara Carla Moura
author_role author
dc.contributor.author.fl_str_mv Cabral, Sara Carla Moura
dc.subject.por.fl_str_mv EGFR
ALK
KRAS
TKI treatment
Adenocarcinoma
Survival
topic EGFR
ALK
KRAS
TKI treatment
Adenocarcinoma
Survival
description Trabalho final de mestrado integrado em Medicina, apresentado à Faculdade de Medicina da Universidade de Coimbra.
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/30456
http://hdl.handle.net/10316/30456
TID:201626268
url http://hdl.handle.net/10316/30456
identifier_str_mv TID:201626268
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133717784952832

Registros relacionados